Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 5/20 | 0.50 |
| ▸ | FNTB | P49356 | 5/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL302957 | 1.00 | LMNA (0.53) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL302958 | 1.00 | LMNA (0.53) | LMNAMAPK1ALDH1A1USP2TP53 | |
| Hydrochloric Acid SCHEMBL10423086 | 0.86 | LTA4H (0.45) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL302152 | 0.86 | FNTA (0.58) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL302151 | 0.86 | FNTA (0.58) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL4952873 | 0.85 | LMNA (0.53) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL25724229 | 0.85 | LMNA (0.53) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL6308975 | 0.85 | MAPK1 (0.54) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL7636762 | 0.84 | FNTA (0.56) | LMNAMAPK1ALDH1A1USP2TP53 | |
| SCHEMBL7636751 | 0.84 | FNTA (0.56) | LMNAMAPK1ALDH1A1USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110020914-A1 | METHODS FOR ENHANCING GROWTH OF ORGANISMS IN AN AQUEOUS GROWTH MEDIUM | NOVUS INTERNATIONAL INC (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2010126794-A1 | METHODS FOR INCREASING GROWTH AND YIELD OF PLANTS WITH METHIONINE COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20070231377-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | NOVUS INTERNATIONAL INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231377-A1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | FGF1, MTR, HGF | LMNA 4267/4885MAPK1 3232/4885ALDH1A1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.